# US 2023/0026696 A1 · Trpv4 receptor ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0026696 A1
- Document ID: US20230026696A1
- Status: Published application
- Kind: A1
- Application number: 17/778,584
- Filed: 2020-11-20
- Published: 2023-01-26
- Earliest claimed: 2019-11-21
- Assignees: University of Utah Research Foundation
- Applicants: University of Utah Research Foundation
- Inventors: Paul Richard Sebahar; Ryan Looper; David Krizaj; Christopher A. Reilly; Seth Wilson Grant
- Web page: https://patentgrep.com/patent/US20230026696A1

## CPC

- A61K 31/337: having four-membered rings, e.g. taxol
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61P 27/02: Ophthalmic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07F 9/568: Four-membered rings
- A01K 2207/30: Animals modified by surgical methods
- A01K 2217/00: Genetically modified animals
- A01K 2227/10: Mammal
- A01K 2227/105: Murine
- A01K 2267/0375: Animal model for cardiovascular diseases
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Described are receptor ligands of transient receptor potential cation channel subfamily V member 4 (TRPV4), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ocular disorders.

## Claims

### Claim 1

A compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
L1 is —C(O)—, —S(O2)—, —S(O)—, or C1-C4alkylene;
X is O or NR1;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, or 4;
Ar1 and Ar2 are each independently selected from a 5-10 membered aryl or heteroaryl;
Z is CR2R3, COR4, or NHR5;
R1 is selected from hydrogen and C1-C4alkyl;
R2, R3, R4, and R5 are each independently selected from the group consisting of hydrogen, hydroxy, C1-C6alkyl, hydroxy-C1-C6alkyl, C1-C6alkoxy, C1-C6alkoxy-C1-C6alkyl, phosphate, C1-C6alkyl phosphate, C4-C8heterocycyl, NR6R7, —OC(O)R8, —C(O)R9, —S(O)2R10, and —OS(O)2R11;
R6, R7, R8, R9, R10, and R11 are each independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6heteroalkyl, C1-C6alkoxy, C4-C8cycloalkyl, C4-C8heterocycyl, C5-C8aryl, C5-C8heteroaryl, C1-C6alkoxy-C1-C6alkyl, C5-C8aryl-C1-C6alkyl, C5-C8heteroaryl-C1-C6alkyl, C5-C8heterocycyl-C1-C6alkyl, amino-C1-C6alkyl, hydroxy-C1-C6alkyl, hydroxy-C3-C8cycloalkyl, cyano-C1-C6alkyl, hydroxysulfonyl-C1-C6alkyl, phosphate-C1-C6alkyl, alkylphosphate-C1-C6alkyl, —COR12, and —CR13R14C(O)R15;
R12 is selected from the group consisting of C1-C6alkyl, C1-C6heteroalkyl, C1-C6alkoxy, amino-C1-C6alkyl, C4-C8heterocycyl, hydroxy-C1-C6alkyl, amino-C4-C8heterocycyl, phosphate-C1-C6alkyl, and C1-C6alkyl phosphate;
R13 and R14 are each independently selected from the group consisting of hydrogen, C1-C6alkyl and, C1-C6heteroalkyl, or optionally taken together with the atoms to which they are attached to form a ring; and
R15 is hydroxy, C1-C6alkoxy or amino;
wherein at least one of m and n is not zero and each aryl, heteroaryl, cycloalkyl, or heterocycle is independently unsubstituted or substituted with one or more substituents independently selected from cyano, halo, C1-C6alkyl, C1-C6alkoxy, amino-C1-C6alkyl, haloalkyl, sulfonyl, —C(O)—C1-C6alkoxy, and —C(O)—NH2.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein L1 is —S(O2)—.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein Ar1 is selected from a 5-membered aryl, a 5-membered heteroaryl, a 6-membered aryl, or a 6-membered heteroaryl,
wherein each aryl or heteroaryl is unsubstituted or substituted with one or two substituents independently selected from cyano, halo, C1-C6alkyl, C1-C6alkoxy, haloalkyl, sulfonyl, and —C(O)—C1-C6alkoxy.

### Claim 4 (depends on 3)

The compound of claim 3, or a pharmaceutical salt thereof, wherein the halo is fluoro or chloro.

### Claim 5 (depends on 3)

The compound of claim 3, or a pharmaceutical salt thereof, wherein the haloalkyl is trifluoromethyl.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein Ar1 is

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein Ar1 is

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein Ar2 is selected from a 5-membered aryl, a 5-membered heteroaryl, a 6-membered aryl, or a 6-membered heteroaryl,
wherein each aryl or heteroaryl is unsubstituted or substituted with one or two substituents independently selected from cyano, halo, C1-C6alkyl, C1-C6alkoxy, —C(O)—C1-C6alkoxy, and —C(O)—NH2.

### Claim 9 (depends on 8)

The compound of claim 8, or a pharmaceutical salt thereof, wherein the halo is fluoro or chloro.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein Ar2 is

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein Ar2 is

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein
Z is CR2R3, COR4, or NHR5;
R2 and R3 are each independently selected from the group consisting of hydrogen, hydroxy, C1-C6alkoxy, C4-C8heterocycyl, phosphate, NR6R7, —OC(O)R8, and S(O)2R10;
R4 is selected from the group consisting of hydroxy, C1-C6alkoxy, and NR6R7;
R5 is selected from the group consisting of hydrogen, C1-C6alkyl, —C(O)R9, and —S(O)2R10;
R6 and R7 are each independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6heteroalkyl, C4-C8heterocycyl, C1-C6alkoxy-C1-C6alkyl, C5-C8heteroaryl-C1-C6alkyl, C5-C8heterocycyl-C1-C6alkyl, amino-C1-C6alkyl, hydroxy-C1-C6alkyl, hydroxy-C3-C8cycloalkyl, cyano-C1-C6alkyl, hydroxysulfonyl-C1-C6alkyl, alkylphosphate-C1-C6alkyl, —COR12, and —CHR13C(O)R14;
R8 is C5-C8aryl or C5-C8heteroaryl;
R9 is selected from the group consisting of C1-C6alkyl, C1-C6heteroalkyl, amino-C1-C6alkyl, hydroxy-C1-C6alkyl, or —COR12;
R10 is amino-C1-C6alkyl;
R12 is selected from the group consisting of C1-C6alkyl, C1-C6heteroalkyl, C1-C6alkoxy, amino-C1-C6alkyl, C4-C8heterocycyl, amino-C4-C8heterocycyl, phosphate-C1-C6alkyl, and C1-C6alkyl phosphate;
R13 and R14 are each independently selected from the group consisting of hydrogen and C1-C6alkyl; and
R15 is selected from the group consisting of hydroxy, C1-C6alkoxy and amino.

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein Z is —CH2OH, —C(O)OH, NH2, —NHC(O)CH2, —CH2NH2, —CH2NHCH3, —CH2NH(CH2)2OH, —CH2NH(CH2)3OH, —CH2NH(C5H9O), —CH2NH(CH2)2OCH3, —CH2NHCH2(C4H7O), —CH2NHCH2CH3, —CH2NHCH2CH(OH)CH3, —CH2NH(C3H5O), or —CH2NHCH2(C3H5O).

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein m is 1.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein X is O and n is 0.

### Claim 16 (depends on 1)

The compound of claim 1, or a pharmaceutical salt thereof, wherein X is NR1.

### Claim 17 (depends on 16)

The compound of claim 16, or a pharmaceutical salt thereof, wherein R1 is hydrogen.

### Claim 18

The compound of 16, or a pharmaceutical salt thereof, wherein m is 0.

### Claim 19 (depends on 16)

The compound of claim 16, or a pharmaceutical salt thereof, wherein n is 0.

### Claim 20 (depends on 1)

The compound of claim 1, selected from

### Claim 21 (depends on 1)

A pharmaceutical composition comprising an effective amount of at least one compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 21)

A method for the treatment of a disorder associated with Transient Receptor Potential Cation Channel Subfamily V Member 4 (“TRPV4”) receptor activity in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 21.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disorder is ocular hypertension.

### Claim 24 (depends on 22)

The method of claim 22, wherein the disorder is atherosclerosis, disorders related to intestinal edema, post-surgical abdominal edema, local and systemic edema, fluid retention, sepsis, hypertension, inflammation, bone related dysfunctions and congestive heart failure, pulmonary disorders, chronic obstructive pulmonary disorder, ventilator induced lung injury, high altitude induced pulmonary edema, acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, sinusitis/rhinitis, asthma, overactive bladder, pain, motor neuron disorders, genetic gain of function disorders, cardiovascular disease, renal dysfunction, osteoarthritis crohn's disease, colitis, diarrhea, intestinal irregularity (hyperreactivity/hyporeactivity), fecal incontinence, irritable bowel syndrome (IBS), constipation, intestinal pain and cramping, celiac disease, lactose intolerance, or flatulence.
